Learning Objectives:

  • Understand the rationale for potential discontinuation of multiple sclerosis (MS) disease-modifying therapies (DMTs) as people age
  • Describe the main efficacy outcomes of the DISCOMS trial
  • Use this information to help MS patients make informed decisions about the risks and benefits of continuing or discontinuing DMTs as they age.
Session date: 
11/17/2022 - 7:30am to 8:30am CST
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Dr. John Corboy